Skip to main content
Figure 1 | BMC Infectious Diseases

Figure 1

From: Top topics in HCV research arena

Figure 1

Phase II trials: SVR rate and 95% CI with DAA in HCVG1 naives. Blue, Triple combo with Protease Inhibitors (PI) + Pegylated interferon (P) + Ribavirin ( R ). Purple, Triple combo with NS5aPol inhbitors + PR. Yellow, QUAD two antivirals acting on viral protease and polymerase with pegylated interferon + ribavirin. Green, Interferon free combos. They are NOT HEAD TO HEAD STUDIES.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us